OverviewSuggest Edit

Aptevo Therapeutics is a biotech company primarily focused on bringing novel oncology and hematology therapeutics to market. The Company leverages the innovative ADAPTIR™ platform technology, a unique approach to cancer immunotherapy, to improve outcomes for cancer patients. Aptevo’s ADAPTIR technology is suitable for producing immunotherapeutics for oncology, hematology, and autoimmune and inflammatory diseases.

TypePublic
Founded2016
HQSeattle, US
Websiteaptevotherapeutics.com

Latest Updates

Employees (est.) (Dec 2018)118(-2%)
Revenue (FY, 2019)$32.4 M(+41%)
Share Price (Nov 2020)$43.9 (-3%)
Cybersecurity ratingCMore

Key People/Management at Aptevo Therapeutics

Marvin L. White

Marvin L. White

President, Chief Executive Officer & Director
Jeff Lamothe

Jeff Lamothe

SVP and Chief Financial Officer
Scott C. Stromatt

Scott C. Stromatt

Chief Medical Officer
Randy J. Maddux

Randy J. Maddux

SVP and Chief Manufacturing Officer
Jane Gross

Jane Gross

SVP and Chief Scientific Officer
Heather Boussios

Heather Boussios

Acting General Counsel
Show more

Aptevo Therapeutics Office Locations

Aptevo Therapeutics has an office in Seattle
Seattle, US (HQ)
2401 4th Ave #1050
Show all (1)

Aptevo Therapeutics Financials and Metrics

Aptevo Therapeutics Revenue

Embed Graph
View revenue for all periods
Aptevo Therapeutics's revenue was reported to be $32.42 m in FY, 2019
USD

Revenue (Q2, 2020)

473.0k

Net income (Q2, 2020)

(6.8m)

Market capitalization (24-Nov-2020)

182.0m

Closing stock price (24-Nov-2020)

43.9

Cash (30-Jun-2020)

7.6m

EV

177.3m
Aptevo Therapeutics's current market capitalization is $182 m.
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019

Revenue

36.4m14.7m23.1m32.4m

Revenue growth, %

(60%)57%

Cost of goods sold

24.2m5.0m11.2m19.9m

Gross profit

12.3m9.6m11.9m12.5m
Quarterly
USDQ2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

10.2m9.4m7.4m10.8m6.2m4.1m6.8m5.8m7.4m9.0m473.0k

Cost of goods sold

6.5m6.2m488.0k5.9m1.9m1.8m2.5m2.4m3.8m6.0m4.0m

Gross profit

3.6m3.2m6.9m4.9m4.3m2.3m4.3m3.4m1.4m5.1m

Gross profit Margin, %

36%34%93%45%70%56%63%58%19%56%
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019

Cash

9.7m7.1m30.6m12.4m

Accounts Receivable

4.3m2.1m5.2m7.0m

Prepaid Expenses

5.6m6.7m6.9m4.2m

Inventories

6.6m1.0m1.8m6.1m
Quarterly
USDQ2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

5.5m10.9m14.0m22.3m75.8m11.8m7.2m28.4m37.0m21.0m17.7m12.3m7.6m

Accounts Receivable

8.5m3.0m1.9m4.7m528.0k3.1m6.1m6.2m5.8m7.4m7.9m

Prepaid Expenses

3.9m3.8m6.1m5.9m6.4m4.1m4.9m5.2m6.9m5.2m2.2m1.3m641.0k

Inventories

20.1m11.6m8.1m8.0m1.2m1.3m3.0m4.0m4.3m7.0m7.5m
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(112.4m)7.0m(53.7m)(40.4m)

Depreciation and Amortization

3.4m3.1m2.4m2.2m

Inventories

13.7m(567.0k)(757.0k)(4.4m)

Accounts Payable

2.5m195.0k1.3m938.0k
USDQ2, 2016

Financial Leverage

1.2 x
Show all financial metrics

Aptevo Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

C

75/100

SecurityScorecard logo

Aptevo Therapeutics Online and Social Media Presence

Embed Graph

Aptevo Therapeutics News and Updates

Aptevo Therapeutics and Alligator Bioscience Present new Preclinical Data for ALG.APV-527 at the PEGS Virtual Interactive Global Summit

SEATTLE and LUND, Sweden, June 10, 2020 /PRNewswire/ -- Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ bispecific technology platform, and Alligator Bioscience AB (Nasdaq...

Aptevo Therapeutics Reports Third Quarter 2019 Financial Results

Reports Record Net Revenue for IXINITY; Achieves 55% Increase in Year-over-Year Quarterly Net Revenue

Aptevo Therapeutics Reports Second Quarter 2019 Financial Results

Reports Positive Preliminary Top-Line Safety Data for APVO210Phase 1 Single Ascending Dose (SAD) Clinical Study

Aptevo Therapeutics Reports Continued Progress In APVO210 and APVO436 Clinical Trials

Completes Dosing in Single Ascending Dose (SAD) Phase 1 Study of APVO210

Aptevo Therapeutics Reports First Quarter 2019 Financial Results

Achieves 73% Increase in First Quarter 2019 Year-Over-Year IXINITY® Net Revenue

Polycystic Kidney Disease Treatment Market to witness huge growth by 2025 | Angion Biomedica, Aptevo Therapeutics, Celgene

HTF MI recently introduced Global Polycystic Kidney Disease Treatment Market study with in-depth overview, describing about the Product / Industry Scope and elaborates market outlook and status to 2023. Posted via Industry Today. Follow us on Twitter @IndustryToday
Show more

Aptevo Therapeutics Blogs

Aptevo Confirms Receipt of Unsolicited Indication of Interest

SEATTLE, WA / ACCESSWIRE / November 19, 2020 / Aptevo Therapeutics Inc. ("Aptevo") (NASDAQ:APVO), a biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ bispecific technology platform, today announced that it has received an unsolicited

Aptevo Therapeutics and Alligator Bioscience Advancing the Bispecific 4-1BBx5T4 Antibody ALG.APV-527 Into Phase 1 Clinical Development

SEATTLE, WA / ACCESSWIRE / November 16, 2020 / Aptevo Therapeutics Inc. ("Aptevo") (NASDAQ:APVO), a biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ bispecific technology platform, and Alligator Bioscience ("Alligator") (Nasdaq

Aptevo Therapeutics Reports Third Quarter Financial Results and Provides Business Update

$1.5 million of RUXIENCE ® Royalties Earned in the Third Quarter Funding Extends Cash Runway Into Q3 2021 SEATTLE, WA / ACCESSWIRE / November 10, 2020 /   Aptevo Therapeutics Inc. ("Aptevo" or "the Company") (NASDAQ:APVO), a biotechnology company focused on developing novel immuno-oncology

Aptevo Therapeutics to Present at the Society for Immunotherapy of Cancer's (SITC) 35th Virtual Annual Meeting

Aptevo Therapeutics to Present at the Society for Immunotherapy of Cancer's (SITC) 35th Virtual Annual Meeting Content Import Mon, 11/09/2020 - 09:03 Aptevo Therapeutics to Present at the Society for Immunotherapy of Cancer's (SITC) 35th Virtual Annual Meeting 11/09/20 …

Aptevo Therapeutics Announces Second Complete Remission in Ongoing APVO436 Phase 1 Clinical Trial

Aptevo Therapeutics Announces Second Complete Remission in Ongoing APVO436 Phase 1 Clinical Trial Content Import Mon, 11/09/2020 - 06:02 Aptevo Therapeutics Announces Second Complete Remission in Ongoing APVO436 Phase 1 Clinical Trial 11/09/20 This release is …

Aptevo Therapeutics Adopts Limited Duration Stockholder Rights Plan

Aptevo Therapeutics Adopts Limited Duration Stockholder Rights Plan Content Import Sun, 11/08/2020 - 23:20 Aptevo Therapeutics Adopts Limited Duration Stockholder Rights Plan 11/08/20 This release is a backfill from a News Wire General …
Show more

Aptevo Therapeutics Frequently Asked Questions

  • When was Aptevo Therapeutics founded?

    Aptevo Therapeutics was founded in 2016.

  • Who are Aptevo Therapeutics key executives?

    Aptevo Therapeutics's key executives are Marvin L. White, Jeff Lamothe and Scott C. Stromatt.

  • How many employees does Aptevo Therapeutics have?

    Aptevo Therapeutics has 118 employees.

  • What is Aptevo Therapeutics revenue?

    Latest Aptevo Therapeutics annual revenue is $32.4 m.

  • What is Aptevo Therapeutics revenue per employee?

    Latest Aptevo Therapeutics revenue per employee is $274.8 k.

  • Who are Aptevo Therapeutics competitors?

    Competitors of Aptevo Therapeutics include Harpoon Therapeutics, Aeglea Biotherapeutics and XBiotech.

  • Where is Aptevo Therapeutics headquarters?

    Aptevo Therapeutics headquarters is located at 2401 4th Ave #1050, Seattle.

  • Where are Aptevo Therapeutics offices?

    Aptevo Therapeutics has an office in Seattle.

  • How many offices does Aptevo Therapeutics have?

    Aptevo Therapeutics has 1 office.